{
    "Trade/Device Name(s)": [
        "ADVIA Centaur EBV-VCA IgM"
    ],
    "Submitter Information": "Biokit S.A.",
    "510(k) Number": "K233606",
    "Predicate Device Reference 510(k) Number(s)": [
        "K040120"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "LSE"
    ],
    "Summary Letter Date": "July 29, 2024",
    "Summary Letter Received Date": "July 29, 2024",
    "Submission Date": "2023-11-09",
    "Regulation Number(s)": [
        "21 CFR 866.3235"
    ],
    "Regulation Name(s)": [
        "Epstein-Barr Virus Serological Reagents"
    ],
    "Analyte Class(es)": [
        "serology",
        "virology"
    ],
    "Analyte(s)": [
        "IgM antibodies to Epstein-Barr virus viral capsid antigen (VCA)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA)",
        "Plasma (lithium heparin)"
    ],
    "Specimen Container(s)": [
        "Serum separator tube (SST)",
        "EDTA tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur XP system"
    ],
    "Method(s)/Technology(ies)": [
        "Sandwich immunoassay",
        "Acridinium ester chemiluminescent technology"
    ],
    "Methodologies": [
        "Immunoassay",
        "Chemiluminescent assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur EBV-VCA IgM assay for qualitative detection of EBV VCA IgM antibodies in serum and plasma on the ADVIA Centaur XP system",
    "Indications for Use Summary": "Qualitative detection of IgM antibodies to the viral capsid antigen of Epstein-Barr virus in pediatric (2-21 years) and adult serum and plasma (EDTA and lithium heparin) as an aid in the diagnosis of EBV infection, such as infectious mononucleosis, when used with other EBV markers",
    "fda_folder": "Microbiology"
}